Overview

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of ocrelizumab in participants with progressive follicular NHL.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Ocrelizumab